Single B cell screening is a powerful technique for isolating and generating antigen-specific monoclonal antibodies (mAbs). This method, often integrated with high-throughput platforms, allows for efficient detection of antibody secretion and rapid identification of lead clones, thereby accelerating antibody discovery, vaccine design, and the development of targeted therapies. Single B cells are advantageous for its simplicity, as it requires only a small number of cells while maintaining a high efficiency in rapidly obtaining specific mAbs.1
The overall process is as follows:
Immunization: 1-2 months with host species with a specific antigen of interest.
Plasma B cell isolation: Collect antibody-secreting cells from spleen and bone marrow.
Single B cell screening: Protein binding and/or cell-based binding is used to detect and sort positive micro-droplets.
Single-cell sequencing.
High-throughput expression and validation.2
Biointron's high-throughput single B cell screening platform can screen 2*10^6 plasma B-cells from immunized animals. Antigen specific antibody-secreting cells can be isolated, allowing for the detection of potentially rare antibodies and drugs.
References:
Tiller, T. (2011). Single B cell antibody technologies. New Biotechnology, 28(5), 453-457. https://www.sciencedirect.com/science/article/pii/S1871678411000768
Pedrioli, A., & Oxenius, A. (2021). Single B Cell Technologies for monoclonal antibody discovery. Trends in Immunology, 42(12), 1143–1158. https://www.cell.com/trends/immunology/fulltext/S1471-4906(21)00213-1
